Special Considerations for Single Patient Expanded Access/Compassionate Use

When appropriate  — and with approval from FDA, the manufacturer and an IRB —  patients with no other options can gain access to experimental drugs and medical devices. Because insurance typically does not cover expenses associated with approval process, many patients can’t afford what they consider a last chance for hope. WCG IRB provides single patient expanded access reviews at no charge.